NASDAQ · Biotechnology · USD
CDT Equity Inc. (CDT) Stock Analysis
CDT Equity Inc. (CDT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CDT Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.16
- Previous Close
- $0.16
- Day's Range
- 0.14–0.16
- 52-Week Range
- 0.42–28,125.00
- Volume
- 1.68M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.56
Valuation
- Market Cap
- $18.24K
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$39.22M
- Shares Outstanding
- 40.54K
- 1-Year Return
- −99.98%
Dividend and dates
- Avg Volume
- 201.22K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CDT closed at $0.14, −99.98% over 1 year.
CDT Equity Inc. (CDT) has a market capitalization of $18.24K.
In fiscal 2025, CDT reported revenue of $0.00.
CDT Stock Return by Calendar Year
CDT Equity Inc. (CDT) return since Mar 2022: what $10,000 became
- 1 year
- $10,000 $2
- −99.98%
- 3 years
- $10,000 $0.0003
- −99.999997%
- Since Mar 2022
- $10,000 $0.00005
- −99.9999995%
If you had invested $10,000 in CDT Equity Inc. (CDT) at the close on March 28, 2022, the earliest close on record here, it would have been worth $0.00005 at the close on October 21, 2026: −99.9999995% in total, −98.49% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −99.95% |
| 2025 | −99.85% |
| 2024 | −98.48% |
| 2023 | −55.61% |
| 2022 (partial year) | +3.12% |
As of October 21, 2026.
CDT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$39.22M | — |
| 2024 | $0.00 | −$17.80M | — |
| 2023 | $0.00 | −$535.00K | — |
| 2022 | $0.00 | −$4.89M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$36.66M | −$39.22M | — |
| 2024 | $0.00 | — | −$15.11M | −$17.80M | — |
| 2023 | $0.00 | — | −$5.26M | −$535.00K | — |
| 2022 | $0.00 | — | −$3.16M | −$4.89M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
YahooCDT Equity Announces Patent Filing From Sarborg Limited For Its Intellectual Property Covering Novel Solid Forms Of Respiratory Medicine
BenzingaCDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
YahooCDT Equity Inc. Announces Reverse Stock Split
YahooCDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
YahooCDT Equity Partners With QIMA Life Sciences To Develop Several Of The Company's Autoimmune Skin Disease Assets, Including Novel Tapinarof Combinations In Psoriasis And Vitiligo
Benzinga
All 15 articles ↓Show fewer ↑
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
YahooSarborg Shareholder CDT Equity Notes The Company's Successful Application Of Its Patented Signature Intelligence And Quantum Computing Models To Mental Health And Neuropsychiatric Drug Discovery
BenzingaCDT Provides Capital Update and Confirms No Nasdaq Deficiencies
YahooCDT Equity Reports $23M Market Value And No Remaining Nasdaq Deficiencies
BenzingaCDT Equity (CDT) Shares Fall 21% After Hours: Here's What Happened
BenzingaCDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
YahooCDT Equity Appoints James Bligh As CEO
BenzingaCDT Equity Enters Securities Purchase Agreement With Sarborg Investors On July 30, 2026; To Buy 4.76% Of Sarborg
BenzingaCDT Equity Approves 1-For-10 Reverse Stock Split
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B